Obermatt

Kalbe Farma

JKT:KLBF · ID1000125107
PharmaceuticalsLarge

360

85
EV / EBIT90
Price / Owner Earnings53
Owner Earnings Yield92
Dividend Yield89
Price/Sales87
EV / Gross Profit97
Price/Book82
Return on Capital97
Cash Return on Capital86
Return on Equity77
EBIT Margin57
Gross Profitability82
Cash Conversion20
Accruals33
Owner Earnings Margin59
Sales growth31
Profit Growth57
Long-Term EPS Growth67
Owner Earnings Growth61
Reinvestment94
Price momentum3
Debt load91
Refinancing88
Debt Payback100
Liquidity90
Analyst ratings83
Opinion Changes71
Price Target Upside90
Market mood67
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kalbe Farma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryIndonesia
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeIDX
Founded1966
Employees2,802
ISINID1000125107
Last UpdateApr 2, 2026
Themes
Health DiagnosticsNutraceuticalCardiovascularOncologyNeurologyFast-Moving Consumer GoodsHealth CarePharmaceutical

Description

PT Kalbe Farma Tbk., primarily operates in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company focuses on providing high-quality healthcare products and services…

Analysis

Bargain bin

PT Kalbe Farma Tbk. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 8.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -6% a year, against analyst forecasts of 11%. The price, in other words, assumes less than the experts do.

Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
94
2023202420252026

All-time high

96

May 2023

All-time low

65

Jan 2024

Average rank

88

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
87
73
69
65
Price/Earnings
90
70
58
48
Price/Book
82
66
59
55
Dividend Yield
89
82
71
71
Value (overall)
94
81
75
59

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kalbe Farma with its peers
Mega Lifesciences
SET:MEGA
78
CountryThailand
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Aurobindo Pharma
NSI:AUROPHARMA
60
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Alkem Laboratories
NSI:ALKEM
47
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Bangkok Lab and Cosmetic
SET:BLC
55
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aspen Pharmacare
JNB:APN
22
CountrySouth Africa
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →